Clinical Trial Update: Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF) [Phase 2]

View source ↗

Summary

The Phase 2 trial evaluating the Extracorporeal Liver Assist Device (ELAD) for fulminant hepatic failure has been withdrawn. No further safety or efficacy data …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fulminant Hepatic Failure

Drugs mentioned

• ELAD (extracorporeal liver assist device)

Snippet

Sponsor: Vital Therapies, Inc. | Conditions: Fulminant Hepatic Failure | Phase 2 | Status: WITHDRAWN